Ignite Creation Date:
2024-05-06 @ 7:27 PM
Last Modification Date:
2024-10-26 @ 3:07 PM
Study NCT ID:
NCT06017869
Status:
RECRUITING
Last Update Posted:
2024-06-11
First Post:
2023-08-24
Brief Title:
Evaluate the Safety and Therapeutic Effects of Transplantation of MNV-201 in Pediatric Patients With Pearson Syndrome
Sponsor:
Minovia Therapeutics Ltd
Organization:
Minovia Therapeutics Ltd
Study Overview
Official Title:
A Phase I Open Label Single Dose Clinical Study to Evaluate the Safety and Therapeutic Effects of Transplantation of MNV-201 in Pediatric Patients With Pearson Syndrome
Status:
RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary Mitochondrial diseases are a clinically and genetically heterogeneous group of disorders caused by mutations in genes encoded by nuclear Deoxyribonucleic Acid DNA or by mutations andor deletions in the mitochondrial DNA mtDNA While some mitochondrial disorders only affect a single organ eg the eye in Leber hereditary optic neuropathy LHON many involve multiple organs Mitochondrial disorders may present at any age and a frequent feature is the increasing number of organs involved in the course of the disease
Minovia Therapeutics Ltd Minovia is a biotech company developing novel therapeutics based on its mitochondrial augmentation technology MAT MNV-201 is a cell therapy produced by MAT that consists of the participants autologous CD34 hematopoietic stem and progenitor cells HSPCs enriched with allogeneic placental-derived mitochondria manufactured in Minovias GMP facility
Minovia Therapeutics Ltd Minovia is a biotech company developing novel therapeutics based on its mitochondrial augmentation technology MAT MNV-201 is a cell therapy produced by MAT that consists of the participants autologous CD34 hematopoietic stem and progenitor cells HSPCs enriched with allogeneic placental-derived mitochondria manufactured in Minovias GMP facility
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None